Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Pavunalimab · XMAB-22841

Bispecific antibody · Immune activation, directed at cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and lymphocyte activation gene 3 protein (LAG3) · developed by Xencor

Phase 1 Most advanced trial (none active)
XNCR Developer
2 Registered trials

What is Pavunalimab?

Pavunalimab is an Fc-engineered bispecific antibody that binds the inhibitory checkpoint receptors CTLA-4 and LAG-3 on T cells in the tumor microenvironment. Dual blockade of these receptors is intended to enhance T-cell activation and proliferation. It is being studied in multiple solid tumors, including melanoma, lung, breast, gastric and ovarian cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
XMAB-22841, CTLA-4 X LAG3, Bavunalimab, XmAb22841
Drug type
Bispecific antibody
Targets
cytotoxic T-lymphocyte-associated protein 4 (CTLA4), lymphocyte activation gene 3 protein (LAG3)
Mechanism
Immune activation, directed at cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and lymphocyte activation gene 3 protein (LAG3)
Pathways
T-cell activation, T-cell proliferation
Therapy area
Oncology
Developer
Xencor, Inc. (XNCR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
3PT70X17VS

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05695898 Phase 1 Metastatic Melanoma Terminated XNCR
NCT03849469 Phase 1 Melanoma Completed XNCR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced or Metastatic Solid TumorsCervical CarcinomaEpithelial Ovarian CancerGastric or Gastroesophageal Junction AdenocarcinomaHepatocellular CarcinomaMelanomaNasopharyngeal CarcinomaNon-small Cell Lung CarcinomaPancreatic CarcinomaProstate CarcinomaRenal Cell CarcinomaSmall Cell Lung CarcinomaSquamous Cell Carcinoma of the Head and NeckTriple Negative Breast Cancer

Other drugs acting on CTLA4 / LAG3

More from Xencor

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.

Follow XNCR, the company behind Pavunalimab

See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XNCR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.